New Therapeutic Targets in the Treatment of Generalized Myasthenia Gravis: Understanding Disease Pathways and Pharmacist-Led Strategies for Optimized Care

Program Description

Generalized myasthenia gravis (gMG) can result in significant disease burden for patients due to fluctuating, often severe, muscle weakness, debilitating fatigue, and a high potential for respiratory crises. Research into the pathophysiology of gMG has uncovered several immunopathologic mechanisms contributing to the disease, particularly the critical roles of autoantibodies, complement activation, and the neonatal Fc receptor (FcRn). This session will provide specialty pharmacists with a foundational understanding of gMG pathophysiology and the latest approved and emerging agents, including FcRn inhibitors, complement inhibitors, and B-cell–directed therapies, with a review of their mechanism of action, efficacy, and safety profiles. Specialty pharmacists must be familiar with the clinical data and access considerations to ensure timely and appropriate care for patients with gMG. By reviewing these novel treatments and detailing the evolving responsibilities of the specialty pharmacist in care coordination, patient education, adherence monitoring, and adverse effect management, this session will support specialty pharmacists in successfully navigating the treatment landscape of gMG. Patient case discussions will also be incorporated, providing opportunities to apply knowledge of gMG management and treatment selection to complex, real-world patient scenarios.

Target Audience: Specialty Pharmacist

Type of Activity: Application

Release date: November 21, 2025

Expiration date: November 21, 2026

Learner level: Foundational, Intermediate

Time to complete activity: 1.5 hour

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the immunopathologic mechanisms contributing to generalized myasthenia gravis (gMG), including the role of autoantibodies, complement, and the neonatal Fc receptor (FcRn)
• Analyze emerging and approved therapies for gMG, including FcRn inhibitors, complement inhibitors, and B-cell directed therapies, in the context of mechanism of action, efficacy, and safety
• Identify the evolving role of specialty pharmacists in managing gMG, including coordination of care, patient education, treatment adherence, and adverse effect management

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-378-H01-P. The activity is available for CE credit through November 21, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Erica Marini, PharmD, MS, BCPS, has no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Liza Patel, PharmD; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose

Pharmacy Times® Editorial Staff— Aislinn Antrim

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms